Paragon offers development and manufacturing services for a variety of biopharmaceuticals. Credit: Pexels from Pixabay.

Catalent has closed an acquisition of viral vector development and gene therapy manufacturing company Paragon Bioservices for $1.2bn.

Having signed an agreement in April this year, Catalent expects Paragon’s scientific capabilities in recombinant viral vectors, vaccines, recombinant proteins and oncolytic viruses will support its biologics business and end-to-end integrated biopharmaceutical solutions.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Paragon’s expertise in adeno-associated virus (AAV) vectors is expected to help Catalent access the $40bn addressable gene therapies market.

Catalent chair and CEO John Chiminski said: “Paragon’s unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth.”

Paragon recently opened a commercial manufacturing centre in Maryland, US. Offering more than 425,000ft² of manufacturing space, the facility includes multiple 500l and 2,000l single-use bioreactors intended for good manufacturing practice (GMP) production of clinical and commercial material.

When the acquisition was initially proposed, Catalent announced plans to finance a part of the capital expansion projects at Paragon’s facilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Paragon is currently working on GMP manufacturing projects with gene therapy developers globally. Catalent intends to continue offering resources to Paragon’s customers and maintain development and manufacturing alliance for its clients.

Paragon employs more than 380 people at its two Maryland sites. All these employees will join Catalent’s existing team of more than 11,000 employees.

Catalent anticipates the acquisition to be accretive to its adjusted net income per share in the second full fiscal year after completion and significantly accretive thereafter.